Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

The $200 Popcorn Popper That Keeps Selling Out

October 1, 2026

Challenged Athletes Foundation Receives Rings of Gold Award from U.S. Olympic & Paralympic Committee

October 1, 2026

CleanChoice Energy Closes Approximately $166M in Project Financing and Tax Equity for Two Solar Projects

October 1, 2026

Fabletics Launches Fabletics Reserve Credit Card, Expanding Value and Loyalty Perks to Its More than 2.7 Million Members

October 1, 2026

First Merchants Bank CEO Mark Hardwick to retire at the end of 2026 and President Mike Stewart to become President and CEO

October 1, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Cancer Vaccine Market Anticipates Robust Growth with a Projected 8.87% CAGR Through 2028
Press Release

Cancer Vaccine Market Anticipates Robust Growth with a Projected 8.87% CAGR Through 2028

By News RoomJanuary 22, 20243 Mins Read
Cancer Vaccine Market Anticipates Robust Growth with a Projected 8.87% CAGR Through 2028
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) — The “Cancer Vaccine Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F” report has been added to ResearchAndMarkets.com’s offering.

The Global Cancer Vaccine Market has seen momentous growth, with the latest industry analysis projecting a notable surge in market value from USD 7.55 billion in 2022 to an expected USD 12.46 billion by 2028. This significant rise reflects a compound annual growth rate (CAGR) of 8.87% during the forecast period.

Cancer vaccines play a crucial role in the future of oncological treatments, utilizing the body’s innate immunity to target and eradicate cancerous cells. The burgeoning market is driven by the soaring demand for preventive vaccines and advancements in vaccine technology, alongside the revolutionary breakthroughs in immunotherapy.

Key Drivers Shaping the Market Landscape

Growth in Preventive Vaccines Sector:
Preventive vaccines, such as those targeting Human Papillomavirus (HPV) and Hepatitis B, have significantly reduced the incidence of related cancers, contributing to the expansion of the market.

Technological Innovations in Vaccine Development: Recent advancements, such as recombinant vaccines and viral vector and DNA cancer vaccines, are charting new territory in cancer care by enhancing personalized treatment effectiveness.

Robust Demand for Immune Checkpoint Inhibitors: A breakthrough in cancer treatment, immune checkpoint inhibitors have transformed oncological therapeutics, propelling the market forward.

Emerging Challenges and Regional Market Insights

The complexity of cancer immunology presents significant challenges, with the need for an in-depth understanding of the cancer-immune system interplay being of utmost importance. Moreover, the intricacies involved in identifying appropriate vaccine targets persist as a challenge.

In the regional context, North America has taken the forefront in the Cancer Vaccines Market, holding the largest market share due to an increasing prevalence of cancer, significant investments in healthcare infrastructure, and concentrated efforts in research and development.

Collaborative Efforts and Segmental Growth Fostering Market Trends

Strategic collaborations and partnerships across various sectors within the healthcare industry have become integral in pushing the boundaries of cancer vaccine research and facilitating the sharing of resources and knowledge.

Vaccine type insights reveal that preventive vaccines continue to dominate the market, while cervical cancer leads in the indication type segment. The recombinant vaccine segment also commands a significant portion of the market share due to the reliance of major industry players on this technology.

The Global Cancer Vaccine Market report delivers a comprehensive analysis of market dynamics, segmentation, regional insights, and the competitive landscape. With the commitment towards understanding intricate market trends and enhancing the understanding of strategies pivotal to market growth, this report is a testament to the relentless pursuit of innovation in the fight against cancer.

Market Players Leading the Charge

  • Merck & Co., Inc.
  • GSK plc
  • Dendreon Pharmaceuticals LLC.
  • Dynavax Technologies.
  • Amgen, Inc.
  • Moderna, Inc.
  • Sanofi SA
  • AstraZeneca Pharmaceuticals LP
  • Bristol-Myers Squibb Company

This analysis aims to empower stakeholders, investors, and professionals in the healthcare sector with the strategic insights needed to navigate the evolving landscape of the Global Cancer Vaccine Market.

Key Attributes:

Report Attribute Details
No. of Pages 170
Forecast Period 2023 – 2028
Estimated Market Value (USD) in 2023 $7.55 Billion
Forecasted Market Value (USD) by 2028 $12.46 Billion
Compound Annual Growth Rate 8.8%
Regions Covered Global

For more information about this report visit https://www.researchandmarkets.com/r/9107ol

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

The $200 Popcorn Popper That Keeps Selling Out

Challenged Athletes Foundation Receives Rings of Gold Award from U.S. Olympic & Paralympic Committee

CleanChoice Energy Closes Approximately $166M in Project Financing and Tax Equity for Two Solar Projects

Fabletics Launches Fabletics Reserve Credit Card, Expanding Value and Loyalty Perks to Its More than 2.7 Million Members

First Merchants Bank CEO Mark Hardwick to retire at the end of 2026 and President Mike Stewart to become President and CEO

Primech Holdings (Nasdaq: PMEC) Unveils Primech Vision, Integrating a Multi-Robot Facility Fleet and Workforce on One Platform; Live Customer Demonstrations Begin October 2026

Easy Environmental Solutions Ships First Commercial EasyFEN™ System to Kenya

The News Forum Presents Aftershock: The World After October 7, 2023

BloFin returns as TOKEN2049 Singapore title sponsor, opens its “NEXT WHALE ERA” chapter with 3rd anniversary afterparty

Editors Picks

Challenged Athletes Foundation Receives Rings of Gold Award from U.S. Olympic & Paralympic Committee

October 1, 2026

CleanChoice Energy Closes Approximately $166M in Project Financing and Tax Equity for Two Solar Projects

October 1, 2026

Fabletics Launches Fabletics Reserve Credit Card, Expanding Value and Loyalty Perks to Its More than 2.7 Million Members

October 1, 2026

First Merchants Bank CEO Mark Hardwick to retire at the end of 2026 and President Mike Stewart to become President and CEO

October 1, 2026

Latest News

Primech Holdings (Nasdaq: PMEC) Unveils Primech Vision, Integrating a Multi-Robot Facility Fleet and Workforce on One Platform; Live Customer Demonstrations Begin October 2026

October 1, 2026

Police seek answers in crash that killed 2 elders, hurt 2 others on BC First Nation

October 1, 2026

An AI agent tried to hack Canadian government website, researchers say

October 1, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version